Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)

被引：5
|
作者：
Weickhardt, A. J. [1 ]
Foroudi, F. [2 ]
Xie, J. [3 ]
Kanojia, K. [3 ]
Sidhom, M. [4 ]
Pal, A. [5 ]
Grimison, P. [6 ]
Zhang, A. [7 ]
Ng, S. [8 ]
Tang, C. [9 ]
Hovey, E. [10 ]
Chen, C. [11 ]
Hruby, G. [12 ]
Guminski, A. [12 ]
Mcjannett, M. [13 ]
Conduit, C. J. [14 ]
Lawrentschuk, N. [15 ]
Tran, B. [16 ]
Davis, I. D. [17 ]
Hayne, D. [18 ]
机构：
[1] Olivia Newton John Canc Wellness & Res Ctr, Med Oncol, Heidelberg, Vic, Australia
[2] Olivia Newton John Canc Wellness & Res Ctr, Radiat Oncol, Heidelberg, Vic, Australia
[3] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[4] Liverpool Hosp, Radiat Oncol, South Western Sydney Local Hlth Dist, Liverpool, NSW, Australia
[5] Liverpool Hosp, Med Oncol, South Western Sydney Local Hlth Dist, Liverpool, NSW, Australia
[6] Chris Obrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia
[7] Chris Obrien Lifehouse, Med Oncol, Camperdown, NSW, Australia
[8] Sir Charles Gairdner Hosp, Med Oncol, Nedlands, WA, Australia
[9] Sir Charles Gairdner Hosp, Radiat Oncol, Nedlands, WA, Australia
[10] Prince Wales Hosp, Med Oncol, Nelune Comprehens Canc Ctr, Randwick, NSW, Australia
[11] Prince Wales Hosp, Radiat Oncol, Nelune Comprehens Canc Ctr, Randwick, NSW, Australia
[12] Royal North Shore Hosp, Radiat Oncol, St Leonards, NSW, Australia
[13] ANZUP Canc Clin Trials, Clin Trials Res, Camperdown, NSW, Australia
[14] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[15] Peter MacCallum Canc Ctr, Urol, Melbourne, Vic, Australia
[16] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[17] Monash Univ, Med Oncol, Eastern Hlth Clin Sch, Box Hill, Vic, Australia
[18] Fiona Stanley Hosp, Urol, Murdoch, WA, Australia
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1817
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1739P
引用
收藏
页码：S1332 / S1332
页数：1
相关论文
共 50 条
  • [31] Impact of non-muscle invasive bladder cancer treatment history on the efficacy of pembrolizumab for patients with metastatic urothelial carcinoma
    Taoka, R.
    Kobayashi, T.
    Hidaka, Y.
    Abe, H.
    Morita, S.
    Ogawa, O.
    Nishiyama, H.
    Kitamura, H.
    Sugimoto, M.
    EUROPEAN UROLOGY, 2022, 81 : S1340 - S1341
  • [32] A phase II trial of risk-adapted treatment for muscle invasive bladder cancer after neoadjuvant accelerated MVAC.
    Geynisman, Daniel M.
    Abbosh, Philip
    Zibelman, Matthew R.
    Feldman, Rebecca
    McConkey, David James
    Hahn, Noah M.
    Bivalacqua, Trinity
    Trabulsi, Edouard John
    Lallas, Costas D.
    Hoffman-Censits, Jean H.
    Viterbo, Rosalia
    Horwitz, Eric M.
    Churilla, Thomas M.
    Alpaugh, R. Katherine
    Greenberg, Richard E.
    Smaldone, Marc C.
    Uzzo, Robert
    Chen, David
    Kutikov, Alexander
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [33] A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).
    Woodcock, Victoria K.
    Purshouse, Karin
    Butcher, Chrissie
    Haddon, Caroline
    Verrall, Gillian
    Elhussein, Leena
    Salio, Mariolina
    Middleton, Mark R.
    Cerundolo, Vincenzo
    Crew, Jeremy
    Protheroe, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [34] Tolterodine in the treatment of overactive bladder:: Analysis of the pooled Phase II efficacy and safety data
    Larsson, G
    Hallén, B
    Nilvebrant, L
    UROLOGY, 1999, 53 (05) : 990 - 998
  • [35] Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial
    Valérie Fonteyne
    Piet Dirix
    Sara Junius
    Elke Rammant
    Piet Ost
    Gert De Meerleer
    Martijn Swimberghe
    Karel Decaestecker
    BMC Cancer, 17
  • [36] Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial
    Fonteyne, Valerie
    Dirix, Piet
    Junius, Sara
    Rammant, Elke
    Ost, Piet
    De Meerleer, Gert
    Swimberghe, Martijn
    Decaestecker, Karel
    BMC CANCER, 2017, 17
  • [37] Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer A Phase 2 Nonrandomized Clinical Trial
    Zsiros, Emese
    Lynam, Sarah
    Attwood, Kristopher M.
    Wang, Chong
    Chilakapati, Shanmuga
    Gomez, Eduardo Cortes
    Liu, Song
    Akers, Stacey
    Lele, Shashikant
    Frederick, Peter J.
    Odunsi, Kunle
    JAMA ONCOLOGY, 2021, 7 (01) : 78 - 85
  • [38] Efficacy and safety analysis of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer
    Yu, Yanhang
    Zhang, Chuanao
    Chen, Hao
    Zhang, Jianglei
    Ouyang, Jun
    Zhang, Zhiyu
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [39] Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy for muscle-invasive bladder cancer: A multi-center, single-arm, phase II trial
    Yang, C.
    Huang, H.
    Zeng, X.
    Dai, H.
    Zhou, G.
    Wang, S.
    Hu, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S1148 - S1148
  • [40] A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results
    Pruthi, Raj S.
    Nielsen, Matthew
    Heathcote, Samuel
    Wallen, Eric M.
    Rathmell, W. Kim
    Godley, Paul
    Whang, Young
    Fielding, Julia
    Schultz, Heather
    Grigson, Gayle
    Smith, Angela
    Kim, William
    O'Donnell, Peter H.
    BJU INTERNATIONAL, 2010, 106 (03) : 349 - 356
12345